Clinuvel Pharmaceuticals

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

Clinuvel prepares New Drug Application (NDA) for the treatment of erythropoietic protoporphyria (EPP) Executive summary: FDA concludes initial review of datasets on SCENESSE® in EPP FDA deems datasets satisfactory for submission of New Drug Application Pre-NDA meeting with FDA to be scheduled to discuss timelines and procedure Clinuvel will request rolling review of NDA under Fast Track designation Clinuvel to request Priority Review to shorten review from 10 to 6 months Clinuvel Pharmaceuticals [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that the US Food and Drug Administration (FDA) has concluded an initial review of Clinuvel’s clinical data package for its drug SCENESSE® (afamelanotide 16mg) in patients with the orphan (rare) genetic disorder erythropoietic protoporphyria (EPP). The FDA has deemed Clinuvel’s clinical data package satisfactory for submitting a New Drug Application (NDA).FDA SUBMISSION PROCESS In January 2016 the FDA requested that Clinuvel submit clinical datasets generated from trials of SCENESSE® in EPP conducted between 2006 and 2013. The need to understand the severity of EPP symptoms and clinical effectiveness of SCENESSE® were the basis of FDA’s request. After a four month review the FDA concluded that the data generated is both satisfactory and sufficient for Clinuvel to submit its NDA dossier. In accordance with 21 CFR Section 314.5 the dossier comprises seven technical sections (chemistry, manufacturing and controls, nonclinical pharmacology and toxicology, human pharmacokinetics and bioavailability, clinical data, statistics) and other pertinent information, including labelling, patents and company financials.1 A pre-NDA meeting will now be organised between the FDA and Clinuvel.Clinuvel will request a rolling review of its NDA dossier under its designation of Fast Track to SCENESSE®, announced to the Australian Securities Exchange (ASX) on July 6, 2016. Clinuvel will request a Priority Review from the FDA to shorten the dossier review time from 10 months to 6 months. Data from 352 patients who participated in five trials in EPP between 2006 and 2013, as well as data from over 200 patients who received the drug during compassionate use and special access programs, will be submitted. Additional data from other patient populations who have been exposed to SCENESSE® will be part of the scientific dossier. The FDA has initiated an EPP workshop on October 24 to learn more about the disease and the effectiveness and safety of the proposed treatment.SCENESSE® was granted orphan drug designation by the FDA in 2008. As a result, the FDA will waive all PDUFA user fees usually required during the submission process. COMMENTARY “Since 2008 Clinuvel has regularly consulted  with the FDA throughout Phase I, II and III of its clinical program, and we have since submitted annual reports to update the Agency on our progress,” Clinuvel’s Director of Regulatory Affairs, Nicoletta Muner said. “Today’s FDA outcome is a direct result of a decade of our team’s consistency, dedication and transparency in negotiating the best pathway with the Agency.“I am very much looking forward to achieving the milestone of presenting the FDA with a quality dossier. Our submission will serve for years to come as a basis for further development and new indications with SCENESSE®,” Dr Muner said.“The FDA Division seems to justly balance scientific data and patients’ experiences with SCENESSE®,” Clinuvel’s Chair, Stan McLiesh said. “The NDA filing will be the next significant step towards making SCENESSE® available in North America, where patients have been vocal in requesting the drug for some time.“After a complex and difficult journey spanning more than a decade I am proud and delighted that Clinuvel’s teams continue to meet longstanding company objectives in the development of SCENESSE®. I thank our active investors for the confidence they place in Clinuvel. Most importantly, the patients are to be commended for their participation in the US trials.”PUBLICATIONS OF SCENESSE® IN EPP A first-in-class drug, SCENESSE® activates the pigment melanin in skin, providing a barrier which protects skin cells from light (photoprotection). The drug also acts as an anti-oxidant. SCENESSE® is delivered via a subcutaneous dissolving implant approximately the size of a grain of rice. Increased pigmentation of the skin appears after two days and lasts up to two months.Results from three clinical trials of SCENESSE® in EPP have been peer-review published. Results from the Phase II CUV010 study were published in both the New England Journal of Medicine and Photochemisty and Photobiology in 2009. Results from the Phase III studies CUV029 (Europe) and CUV039 (USA) were published in the New England Journal of Medicine in 2015.2Data from ongoing use of the drug – up to eight years in some patients – from compassionate use and expanded access programs were published in the British Journal of Dermatology in 2015.3EUROPEAN DISTRIBUTION OF SCENESSE® SCENESSE® was approved by the European Medicines Agency in 2014 under EC2004/726 article 14(8) and is now commercially available for the prevention of phototoxicity in adult EPP patients.4 The drug has a positive safety profile which continues to be monitored through a strict European post-authorisation pharmacovigilance program comprising an EPP Disease Registry. - End –References & Notes1 21 CFR Section 314.5 2 Harms J, Minder CE, Minder EI, (2009). An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. NEJM, 360(3):306-307.Harms J et al (2009). Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol 85(6):1434-9.Langendonk J et al (2015). Afamelanotide for Erythropoietic Protoporphyria. NEJM. 373(1):48-59. 3 Biolcati G et al (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. BJD. 172(6):1601-1612. 4 SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in the orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug’s positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on Clinuvel’s website at www.clinuvel.com. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the Clinuvel has identified patient populations with a clinical need for photoprotection and for repigmentation. The worldwide prevalence of these patient groups range from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP).Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, Switzerland, the US and Singapore. For more information go to http://www.clinuvel.com. Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 781 631 3117 This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries This email address is being protected from spambots. You need JavaScript enabled to view it. Forward-Looking Statements This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US. Level 5, 160 Queen Street T +61 3 9660 4900 www.clinuvel.com

Read More
 2016-07-18

Executive summary: FDA awards Fast Track Designation¹ to expedite review of SCENESSE® in EPP NDA filing allowed on a rolling basis FDA hosting a Scientific Workshop² on EPP to learn more about disease and drug treatment Clinuvel Pharmaceuticals [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced that the US Food and Drug Administration (FDA) has granted SCENESSE® (afamelanotide 16 mg) Fast Track designation for the treatment of erythropoietic protoporphyria (EPP). This designation recognises the severity of EPP and the unmet medical need of the disorder in the US. SCENESSE® is commercially available for EPP patients in Europe.3US FDA REVIEW PROCESS Clinuvel has been in regular contact with the FDA since 2009 to discuss its clinical trial program, the complexity of EPP and the unique nature of SCENESSE® as a new molecular entity. Fast Track designation has been recommended following an initial FDA review of the Clinuvel data sets requested by the relevant scientific division of the FDA in early 2016.The Fast Track designation enables Clinuvel to file a New Drug Application (NDA) on a rolling basis for US regulatory assessment. A pre-NDA meeting will be scheduled shortly with the FDA to discuss the timing of the first filing of the scientific dossier which will also be eligible for priority review, allowing an abbreviated review time of approximately six months.The FDA intends to host a Scientific Workshop² on EPP on October 24 to learn more about the impact of EPP on patients and the proposed drug treatment.In 2008, the Office for Orphan Products of the FDA awarded SCENESSE® orphan designation for EPP. Significant advantages of the orphan designation include substantially lower NDA filing fees and market exclusivity for seven years following first market access in the US. US EPP COMMUNITY Since the commencement of a US clinical program for EPP in 2009 Clinuvel has received a large number of US patient requests to access SCENESSE®. Clinuvel has communicated to patients and patient associations that it must await US regulatory clearance for the drug. There is a strong network of expert EPP treatment centres in the US, coordinated by the US Porphyrias Consortium. Expert centres will be notified of the expedited US regulatory process to make the treatment available to their patients.COMMENTARY “This is excellent news for US EPP patients, as Clinuvel has been in productive discussion with the US FDA for a considerable time directed towards making the drug available,” Clinuvel’s Chair, Stan McLiesh said.”The FDA has shown the vision to first look at Clinuvel’s scientific data and agree to a swift review process and involve patients and expert physicians for a comprehensive meeting to learn more about the disease and the potential of the innovative treatment,” Mr McLiesh said.“Looking ahead, we can expect that the FDA will ask Clinuvel to implement strict pharmacovigilance measures once the drug is available in the US, similar to the systems we have now put in place in Europe,” Clinuvel’s Acting Chief Scientific Officer, Dr Dennis Wright said. “We see increasing harmonisation between EMA and FDA when it comes to managing the risks of novel treatments made available to the public. The common regulatory thinking is reflected in an approval process where the voice of patients and physicians is given weight in decision making. Clinuvel’s regulatory team is now being expanded to ensure that the NDA dossier is to a high standard and that we move through this review process swiftly,” Dr Wright said. - End - ¹Food and Drug Administration Modernization Act, 1997. ²FDA Scientific Workshop: 24 October 2016: http://www.fda.gov/drugs/newsevents/ucm501389.htm. 3SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in the orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug’s positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on Clinuvel’s website at www.clinuvel.com. About erythropoietic protoporphyria (EPP) Erythropoietic protoporphyria (EPP) is a rare genetic storage disorder that causes severe anaphylactic-like reactions to light (phototoxicity). Patients complain of burning under the skin, usually within minutes of exposure to bright lights, especially sunlight. The first sensation – phototoxicity – is the result of a chemical reaction taking place underneath patients’ skin which results in burns and damage of the tissues. EPP symptoms can be acute, or delayed (subacute), most often expressed as generalised oedema, effusion in tissues and distortion of the skin. As little as a few minutes of light outdoors (even when it is overcast or transmitted through a window) or artificial light exposure may be sufficient to evoke EPP symptoms. Phototoxicity is unresponsive to traditional pain and burn management techniques and patients can be incapacitated for days before reactions subside. Most patients withdraw from light exposure in order to manage their phototoxic symptoms. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the Clinuvel has identified patient populations with a clinical need for photoprotection and for repigmentation. The worldwide prevalence of these patient groups range from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP).Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, Switzerland, the US and Singapore. For more information go to http://www.clinuvel.com. Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117 This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries This email address is being protected from spambots. You need JavaScript enabled to view it. Forward-Looking Statements This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US. Level 5, 160 Queen Street T +61 3 9660 4900 www.clinuvel.com

Read More
 2016-07-05

First commercial delivery, SCENESSE® approved as standard of care in the Netherlands Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its drug SCENESSE® (afamelanotide 16mg) has been launched in Europe, with the first commercial delivery of the product under European marketing authorisation.1 Patients with the rare genetic disorder erythropoietic protoporphyria (EPP) in the Netherlands will be treated with SCENESSE® starting from this week. First treatments in Austria and Germany are expected in July. SCENESSE® - standard of care in EPP The Netherlands is home to one of the largest known adult EPP patient populations in Europe. Following acceptance of the drug as a specialty hospital product by Dutch authorities, SCENESSE® holds the distinction of being the first ever approved standard of care for EPP, enabling reimbursement of the product for all adult EPP patients in the Netherlands. Insurers in Germany and Austria have also facilitated access to SCENESSE® for EPP patients. All patients treated with SCENESSE® are being encouraged to participate in a post-authorisation non-interventional treatment protocol as part of a disease registry required by the European Medicines Agency. Clinuvel has also established a strict pharmacovigilance system to monitor long term patients’ safety during the commercial phase of the product. Clinuvel is working to make SCENESSE® available across Europe where EPP patient populations are known, focusing initially on those countries where the product has already been used in clinical trials or compassionate use programs. The company is establishing a uniform commercial price across Europe. Commentary "Today is an extremely important day for EPP patients, their families, and the physicians who treat them," Clinuvel's Chair, Mr Stan McLiesh said. "I'm proud that our teams have successfully navigated the onerous European and national systems to arrive at this point, and I look forward to broadening the availability of SCENESSE® in the coming months." "We have identified a small number of European countries who can be considered first adopters in the rare disease space and have recognised the need to treat EPP patients during conditions when light intensity increases," Clinuvel's CEO, Dr Philippe Wolgen said. - End - 1 SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in the orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug’s positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on Clinuvel’s website at www.clinuvel.com. Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117 This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries This email address is being protected from spambots. You need JavaScript enabled to view it. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and for repigmentation. The worldwide prevalence of these patient groups range from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, Switzerland, the US and Singapore. For more information go to http://www.clinuvel.com. SCENESSE® is a registered trademark of Clinuvel Pharmaceuticals Ltd. Forward-Looking Statements This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US. Level 5, 160 Queen Street T +61 3 9660 4900 www.clinuvel.com Melbourne, Victoria 3000 F +61 3 9660 4999 Australia

Read More
 2016-06-22

Response to increasing US investor interest Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced the inclusion of its Sponsored Level 1 American Depository Receipt (ADR) program in Nasdaq’s International Designation, a new visibility offering available to non-US companies. Clinuvel is the first life science company to be selected for this initiative, first launched by Nasdaq on 9 December 2015. Clinuvel’s US Investor Base and Level 1 ADR (CLVLY) Program Clinuvel’s Level I ADRs (CLVLY) have traded on the over-the-counter market since 2004. The Bank of New York Mellon is the depository bank and one ADR represents one ASX-listed ordinary share. The International Designation will provide Clinuvel with access to Nasdaq’s visibility assets. Nasdaq will distribute the company’s news through its press release distribution service, reaching both investor and financial news and online services. Nasdaq is one of the world’s leading electronic stock markets, attracting many companies who focus on innovation. The International Designation is not a listing. The companies who participate in this initiative are not subject to the same listing or qualification standards applicable to securities listed on an exchange. There are no additional regulatory or compliance requirements to what is in place for Level I ADRs.Commentary "Clinuvel’s progress against its corporate objectives has seen in recent months an increase in interest from the US as seen through our ADR program," Clinuvel’s Chief Financial Officer, Darren Keamy said. "As Clinuvel’s US activities expand, and the company eyes the relatively large US therapeutic market, it is natural for us to consider broadening our appeal to US investors, with a US listing a viable option for continued growth. In an uncertain US macroeconomic environment where pharmaceutical companies are being re-rated, we approach this topic methodically. It is our expectation Nasdaq’s International Designation will provide a benefit to the company’s visibility in the US and to its Level I ADR program. "An assessment of the benefits and effectiveness of the International Designation will be made by the Board in due course. In parallel management continues to prepare the company for a number of options to broaden its appeal in the US." Mr Keamy said. Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117 This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries This email address is being protected from spambots. You need JavaScript enabled to view it. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and for repigmentation. The worldwide prevalence of these patient groups range from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, Switzerland, the US and Singapore. For more information go to http://www.clinuvel.com. SCENESSE® is a registered trademark of Clinuvel Pharmaceuticals Ltd. Forward-Looking Statements This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US. Level 5, 160 Queen Street T +61 3 9660 4900 www.clinuvel.com Melbourne, Victoria 3000 F +61 3 9660 4999 Australia

Read More
 2016-06-02

German Porphyria Expert Centres to start distribution of SCENESSE® (afamelanotide 16mg) Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced an update on the company’s post-authorisation distribution of SCENESSE® (afamelanotide 16mg) across Europe for adult patients with the rare disorder erythropoietic protoporphyria (EPP).1 SCENESSE® in EPP SCENESSE® is the first approved treatment for EPP, a genetic disorder characterised by acute phototoxic reactions (anaphylactoid reactions and burns) and forced withdrawal from exposure to all forms of visible light. Clinuvel conducted clinical trials of SCENESSE® in EPP from 2006 to 2013. During this time the company evaluated the treatment in 352 EPP patients. After completion of the clinical trial program, approximately 130 patients across eight countries (Australia, Austria, France, Germany, Italy, Sweden, Switzerland and The Netherlands) received SCENESSE® free of charge. In total 601 implant injections were provided to patients free of charge under compassionate use schemes. The development program and the following compassionate use program was supported entirely by equity funding. Subsidised access to SCENESSE® treatment, prior to the drug’s formal commercial approval, was made possible in both Italy and Switzerland from 2010 and 2012 respectively. These two programs enabled 115 EPP patients to benefit from treatment with SCENESSE® totalling more than 200 patient years of cumulative care. Clinuvel is no longer in the position to provide access to SCENESSE® on a subsidised basis. Regulatory and clinical obligations prior to SCENESSE® distribution The European Medicines Agency (EMA) granted SCENESSE® marketing authorisation under a strict risk management plan, comprising a Post-Authorisation Safety Study (PASS) as well as a Retrospective Chart Review (RCR) to follow up those who do not consent to participate in the PASS. The process of regulatory drug release and approval of the pharmacovigilance systems required a further 18 months of in-depth discussion with the EMA. The EMA’s pharmacovigilance subcommittee (PRAC) formally endorsed the last of these protocols on April 14, 2016. The final regulatory and clinical steps prior to the start of the treatment are a review of the PASS and RCR protocols by some of the local ethics committees and the approval of patient and physician educational materials by various National Competent Authorities. SCENESSE® as High Specialty Care in Porphyria Expert Centres SCENESSE® is only being made available to EPP patients through Porphyria Expert Centres, which require training and accreditation by Clinuvel.In Germany it is anticipated that the first year three Porphyria Expert Centres – in Berlin, Chemnitz, and Düsseldorf – will be able to prescribe the treatment. The German national authorities have released their first assessment of the use of SCENESSE® in EPP. In parallel, 13 German insurance firms have agreed to make SCENESSE® available to EPP patients. It is the company’s expectation for a uniform commercial price to be in place across Europe. Discussions are underway with authorities in nine countries to make SCENESSE® available, with further submissions anticipated in 2016. Supporting rare diseases online Recognising the disparate nature of information on rare diseases online, Clinuvel is launching a new website – in beta version by May 31 and live by July 1 – focusing on the clinical aspects of EPP and research into the disease. The site will also serve to connect patients with Porphyria Expert Centres and diagnostic labs. Commentary ”The long term success of SCENESSE® lies in the safety profile of the product for EPP patients and, hence, our and regulators’ focus on pharmacovigilance,” Clinuvel’s chair, Mr Stan McLiesh said. “Now we look forward to the release of the photoprotective product by the various ethics committees to finally make the wishes of EPP patients a reality.” “After years of subsidising the treatment and providing it free of charge, Clinuvel needs to move towards the next stage of development: investing in a treatment for children with EPP. It has long been our desire to bring light to these children. Both decision makers and the medical community agree that Clinuvel should provide a pharmaceutical answer to EPP children,” Mr McLiesh said. - End - 1SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in the orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug’s positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on Clinuvel’s website at www.clinuvel.com. Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765 This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540 This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117 This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries This email address is being protected from spambots. You need JavaScript enabled to view it. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and for repigmentation. The worldwide prevalence of these patient groups range from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, Switzerland, the US and Singapore. For more information go to http://www.clinuvel.com. SCENESSE® is a registered trademark of Clinuvel Pharmaceuticals Ltd. Forward-Looking Statements This release to the Australian Securities Exchange and to press may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause Clinuvel’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that the FDA may require additional studies beyond the studies planned for product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that Clinuvel may never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US. Level 5, 160 Queen Street T +61 3 9660 4900 www.clinuvel.com Melbourne, Victoria 3000 F +61 3 9660 4999 Australia

Read More
 2016-05-18
JoomlaXTC K2 Content Wall - Copyright 2010-2011 Monev Software LLC

Clinuvel Stock Ticker

Quick Links